FFA
TVRD

Freedman Financial Associates’s Tvardi Therapeutics TVRD Stock Holding History

Freedman Financial Associates’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-93
Closed -$42K – 459
2022
Q1 		$42K Hold
93
– – 0.03% 221
2021
Q4 		$41K Sell
93
-4
-4% -$2.01K 0.03% 231
2021
Q3 		$54K Hold
97
– – 0.04% 186
2021
Q2 		$50K Sell
97
-53
-35% -$33.6K 0.04% 195
2021
Q1 		$117K Hold
150
– – 0.1% 94
2020
Q4 		$82K Buy
+150
New +$78.6K 0.07% 115

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freedman Financial Associates's TVRD Position: Q2 2022 in Review

Freedman Financial Associates sold out of Tvardi Therapeutics (TVRD) in Q2 2022, closing a stake of 93 shares — an estimated $42K sold.

Freedman Financial Associates first reported a position in TVRD in Q4 2020 and held it in 6 quarters. The position peaked at $117K in Q1 2021. 178 funds tracked by Wall St. Rank hold TVRD as of Q2 2022.

  • Freedman Financial Associates reported no remaining Tvardi Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Freedman Financial Associates sold 93 Tvardi Therapeutics shares in Q2 2022, an estimated $42K.
  • Freedman Financial Associates first reported a position in Tvardi Therapeutics in Q4 2020 and held it in 6 quarters.
  • Freedman Financial Associates's Tvardi Therapeutics position peaked at $117K in Q1 2021.
  • 178 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.